FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2513426503> ?p ?o ?g. }

• W2513426503 endingPage "1465" @default.
• W2513426503 startingPage "1455" @default.
• W2513426503 abstract "Objective/Background Intranasal sumatriptan (Imitrex ® ) may be an alternative for patients who refuse injections and cannot tolerate oral agents, but due to low bioavailability and slow absorption, the clinical utility of the currently marketed formulation is limited, highlighting an unmet need for an effective non‐oral migraine medication with a rapid onset of action. To overcome the slow absorption profile associated with intranasal administration, we evaluated the impact of 1‐O‐n‐Dodecyl‐β‐D‐Maltopyranoside (DDM, Intravail A‐3™), a permeation enhancer, on sumatriptan's pharmacokinetic profile by comparing the pharmacokinetic characteristics of two commercial sumatriptan products, 4 mg subcutaneous and 6 mg subcutaneous in healthy adults, with DFN‐02 – a novel intranasal agent comprised of sumatriptan 10 mg plus 0.20% DDM. We also determined the pharmacokinetic characteristics of DDM and evaluated its safety and tolerability. Methods We conducted two studies: a randomized, three‐way crossover study comparing monodose and multidose devices for delivery of single doses of DFN‐02 with commercially available intranasal sumatriptan 20 mg in 18 healthy, fasted adults, and an open‐label, randomized, single‐dose, three‐way crossover bioavailability study comparing DFN‐02 with 4 mg and 6 mg subcutaneous sumatriptan in 78 healthy, fasted adults. In the study comparing DFN‐02 with IN sumatriptan, subjects received a single dose of DFN‐02 (sumatriptan 10 mg plus DDM 0.20%) via monodose and multidose delivery systems with at least 5 days between treatments. In the comparison with SC sumatriptan, subjects received a single dose of each treatment with at least 3 days between treatments. In both studies, blood was sampled for pharmacokinetic evaluation of sumatriptan and DDM through 24 hours post‐dose; safety and tolerability were monitored throughout. Results In the comparison with commercially available intranasal sumatriptan 20 mg, DFN‐02 had a more rapid absorption profile; t max was 15 minutes for DFN‐02 monodose, 10.2 minutes for DFN‐02 multidose, and 2.0 hours for commercially available intranasal sumatriptan 20 mg. Compared with 4 and 6 mg subcutaneous sumatriptan, DFN‐02's median t max (10 minutes) was significantly earlier (15 minutes; P < .0001). Mean sumatriptan exposure metrics were similar for DFN‐02 and 4 mg sumatriptan: AUC 0‐2 : 35.12 and 44.82 ng*hour/mL, respectively; AUC 0‐∞ : 60.70 and 69.21 ng*hour/mL, respectively; C max : 51.79 and 49.07 ng/mL, respectively. With 6 mg subcutaneous sumatriptan, these exposure metrics were about 50% larger (AUC 0–2 : 67.17 ng*hour/mL; AUC 0‐∞ : 103.78 ng*hour/mL; C max : 72.75 ng/mL). Inter‐subject variability of AUC 0‐2 , AUC 0‐∞ , and C max was 42–58% for DFN‐02, 15–22% for 4 mg subcutaneous sumatriptan, and 15–25% for 6 mg subcutaneous sumatriptan. DDM exposure was low (mean C max : 1.63 ng/mL), t max was 30 minutes, and it was undetectable by 4 hours. There were no serious adverse events, discontinuations due to adverse events, or remarkable findings for vital signs, physical examinations (including nasal and injection site examinations), or clinical laboratory assessments. The overall incidence of adverse events was comparable across treatments, and all treatment‐related events were mild in severity. Adverse events occurring in ≥10% of subjects were dysgeusia (19%), headache (18%), nausea (15%), paresthesia (15%), and dizziness (12%). Conclusions In healthy subjects, DFN‐02, an intranasal spray containing 10 mg sumatriptan plus DDM, had a more rapid absorption profile than commercially available intranasal sumatriptan 20 mg, and systemic exposure from a single‐dose administration of DFN‐02 was similar to 4 mg SC sumatriptan and two‐thirds that of 6 mg SC sumatriptan. With DFN‐02, plasma sumatriptan peaked 5 minutes earlier than with both subcutaneous formulations. Systemic exposure to sumatriptan was similar with DFN‐02 and 4 mg subcutaneous sumatriptan; both yielded lower systemic exposure than 6 mg subcutaneous sumatriptan. Systemic exposure to DFN‐02's excipient DDM was short‐lived. DFN‐02's safety and tolerability appear to be comparable to subcutaneous sumatriptan. Addition of a permeation enhancer improved the absorption profile compared with commercially available intranasal sumatriptan 20 mg." @default.
• W2513426503 created "2016-09-16" @default.
• W2513426503 creator A5043272418 @default.
• W2513426503 creator A5050811011 @default.
• W2513426503 creator A5055529892 @default.
• W2513426503 creator A5058076640 @default.
• W2513426503 creator A5074961488 @default.
• W2513426503 creator A5087875269 @default.
• W2513426503 date "2016-09-10" @default.
• W2513426503 modified "2023-09-30" @default.
• W2513426503 title "A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN‐02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults" @default.
• W2513426503 cites W1971084858 @default.
• W2513426503 cites W1980229633 @default.
• W2513426503 cites W1984859656 @default.
• W2513426503 cites W1990078753 @default.
• W2513426503 cites W1990913154 @default.
• W2513426503 cites W1991020694 @default.
• W2513426503 cites W1997177751 @default.
• W2513426503 cites W1998380789 @default.
• W2513426503 cites W2020568108 @default.
• W2513426503 cites W2024112159 @default.
• W2513426503 cites W2034346357 @default.
• W2513426503 cites W2038384570 @default.
• W2513426503 cites W2051662025 @default.
• W2513426503 cites W2059433791 @default.
• W2513426503 cites W2061794406 @default.
• W2513426503 cites W2064979043 @default.
• W2513426503 cites W206543914 @default.
• W2513426503 cites W2075149149 @default.
• W2513426503 cites W2090221102 @default.
• W2513426503 cites W2114413295 @default.
• W2513426503 cites W2123533552 @default.
• W2513426503 cites W2131056140 @default.
• W2513426503 cites W2140200736 @default.
• W2513426503 cites W2157637604 @default.
• W2513426503 cites W2166530830 @default.
• W2513426503 cites W280466403 @default.
• W2513426503 cites W58525860 @default.
• W2513426503 doi "https://doi.org/10.1111/head.12905" @default.
• W2513426503 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27613076" @default.
• W2513426503 hasPublicationYear "2016" @default.
• W2513426503 type Work @default.
• W2513426503 sameAs 2513426503 @default.
• W2513426503 citedByCount "23" @default.
• W2513426503 countsByYear W25134265032017 @default.
• W2513426503 countsByYear W25134265032018 @default.
• W2513426503 countsByYear W25134265032019 @default.
• W2513426503 countsByYear W25134265032020 @default.
• W2513426503 countsByYear W25134265032021 @default.
• W2513426503 countsByYear W25134265032022 @default.
• W2513426503 countsByYear W25134265032023 @default.
• W2513426503 crossrefType "journal-article" @default.
• W2513426503 hasAuthorship W2513426503A5043272418 @default.
• W2513426503 hasAuthorship W2513426503A5050811011 @default.
• W2513426503 hasAuthorship W2513426503A5055529892 @default.
• W2513426503 hasAuthorship W2513426503A5058076640 @default.
• W2513426503 hasAuthorship W2513426503A5074961488 @default.
• W2513426503 hasAuthorship W2513426503A5087875269 @default.
• W2513426503 hasConcept C112705442 @default.
• W2513426503 hasConcept C126322002 @default.
• W2513426503 hasConcept C142724271 @default.
• W2513426503 hasConcept C170493617 @default.
• W2513426503 hasConcept C181389837 @default.
• W2513426503 hasConcept C197934379 @default.
• W2513426503 hasConcept C204787440 @default.
• W2513426503 hasConcept C27081682 @default.
• W2513426503 hasConcept C2778375690 @default.
• W2513426503 hasConcept C2778541695 @default.
• W2513426503 hasConcept C2778871607 @default.
• W2513426503 hasConcept C2778938600 @default.
• W2513426503 hasConcept C2780973058 @default.
• W2513426503 hasConcept C42219234 @default.
• W2513426503 hasConcept C42404028 @default.
• W2513426503 hasConcept C71924100 @default.
• W2513426503 hasConcept C85663871 @default.
• W2513426503 hasConcept C87813604 @default.
• W2513426503 hasConcept C98274493 @default.
• W2513426503 hasConceptScore W2513426503C112705442 @default.
• W2513426503 hasConceptScore W2513426503C126322002 @default.
• W2513426503 hasConceptScore W2513426503C142724271 @default.
• W2513426503 hasConceptScore W2513426503C170493617 @default.
• W2513426503 hasConceptScore W2513426503C181389837 @default.
• W2513426503 hasConceptScore W2513426503C197934379 @default.
• W2513426503 hasConceptScore W2513426503C204787440 @default.
• W2513426503 hasConceptScore W2513426503C27081682 @default.
• W2513426503 hasConceptScore W2513426503C2778375690 @default.
• W2513426503 hasConceptScore W2513426503C2778541695 @default.
• W2513426503 hasConceptScore W2513426503C2778871607 @default.
• W2513426503 hasConceptScore W2513426503C2778938600 @default.
• W2513426503 hasConceptScore W2513426503C2780973058 @default.
• W2513426503 hasConceptScore W2513426503C42219234 @default.
• W2513426503 hasConceptScore W2513426503C42404028 @default.
• W2513426503 hasConceptScore W2513426503C71924100 @default.
• W2513426503 hasConceptScore W2513426503C85663871 @default.
• W2513426503 hasConceptScore W2513426503C87813604 @default.
• W2513426503 hasConceptScore W2513426503C98274493 @default.
• W2513426503 hasIssue "9" @default.
• W2513426503 hasLocation W25134265031 @default.

• next